$MDCO (The Medicines Company)

$MDCO {{ '2016-06-27T14:31:14+0000' | timeago}} • Announcement

$MDCO said it closed divestiture of its non-core cardiovascular assets, Cleviprex (clevidipine) injectable emulsion, Kengreal (cangrelor) and rights to Argatroban for Injection to Chiesi USA and its parent company Chiesi Farmaceutici. $MDCO received about $264MM in cash and has potential to receive up to $480MM in sales-based milestone payments.

$MDCO {{ '2017-08-30T13:09:58+0000' | timeago}} • Announcement

$MDCO said the FDA has approved Vabomere (meropenem and vaborbactam) for injection for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.

$MDCO {{ '2017-08-28T12:09:36+0000' | timeago}} • Announcement

$MDCO and $ALNY announced positive data from the ORION-1 Phase II study of Inclisiran, an investigational, drug for the treatment of high cholesterol. The companies added that there were no deaths or serious adverse events during the extended observation period.

$MDCO {{ '2017-03-31T12:13:59+0000' | timeago}} • Announcement

$MDCO has appointed Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos, who will serve as a Class I director, will stand for election at the company’s 2017 Annual Meeting of Stockholders.

$MDCO {{ '2017-02-28T12:55:08+0000' | timeago}} • Announcement

$MDCO's revenue for 4Q16 dropped to $25.2MM from $67.2MM last year. Included in revenue for 4Q16 was $9.1MM of royalty revenues derived from the gross profit on authorized generic sales of Angiomax (bivalirudin) by Sandoz, Inc. Worldwide Angiomax/Angiox (bivalirudin) net product sales fell to $7.8MM from $23.2MM.

$MDCO {{ '2017-02-28T12:54:45+0000' | timeago}} • Announcement

$MDCO reported a wider 4Q16 loss from continuing operations due to lower revenue. Loss from continuing operations widened to $124.43MM or $1.77 per share from $68.24MM or $0.99 per share last year. Adjusted loss per share widened to $1.19 from $0.86.

$MDCO {{ '2016-09-21T12:38:06+0000' | timeago}} • Announcement

$MDCO said the initial $32MM award will support a Phase IIIb trial of its investigational antibiotic, Carbavance, for treatment of gram-negative infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

$MDCO {{ '2016-09-21T12:37:05+0000' | timeago}} • Announcement

$MDCO said Biomedical Advanced Research and Development Authority (BARDA) will provide $32MM in initial funding, and up to an additional $100MM over about 5 years if all options to extend partnership are exercised by BARDA.

$MDCO {{ '2016-09-21T12:35:47+0000' | timeago}} • Announcement

$MDCO entered into a new strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA). The partnership was established under U.S. Department of Health and Human Services' (HHS) Other Transactional Authority (OTA) and is a distinctive, flexible, portfolio-based approach to funding drug development.

$MDCO {{ '2016-09-21T12:34:51+0000' | timeago}} • Announcement

$MDCO received up to $132MM to develop portfolio of new antibiotics targeting drug-resistant gram-negative infections under strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA).

$MDCO {{ '2016-08-31T15:14:41+0000' | timeago}} • Announcement

$MDCO said it provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).

$MDCO {{ '2016-06-27T14:35:50+0000' | timeago}} • Announcement

$MDCO said it expects a reduction in annual selling, general and administrative and related research and development expenses of between $65MM and $80MM. After closing this deal, $MDCO will have executed two transactions with the potential to generate up to $1.2Bil in non-dilutive cash.

$MDCO {{ '2016-06-27T14:31:14+0000' | timeago}} • Announcement

$MDCO said it closed divestiture of its non-core cardiovascular assets, Cleviprex (clevidipine) injectable emulsion, Kengreal (cangrelor) and rights to Argatroban for Injection to Chiesi USA and its parent company Chiesi Farmaceutici. $MDCO received about $264MM in cash and has potential to receive up to $480MM in sales-based milestone payments.

$MDCO {{ '2016-06-15T16:33:20+0000' | timeago}} • Announcement

$MDCO said the Phase 2-3 development program for ABP-700 has been named VERONA by the company. The first Phase 2 study in the VERONA Program is expected to enroll 75 patients undergoing elective colonoscopies at three sites in The Netherlands. The study tests three ABP-700 infusion regimens with goal of enabling successful procedure completion.

$MDCO {{ '2016-06-15T16:32:13+0000' | timeago}} • Announcement

$MDCO said it has dosed the first patient in a Phase 2 study of ABP-700 in procedural sedation. The Phase 2 study follows within weeks of completion of Phase 1 clinical pharmacology, dosing and safety studies, including its use with pre- and co-medications routinely given as part of procedural sedation and induction of general anesthesia.

$MDCO {{ '2016-06-02T20:09:07+0000' | timeago}} • Announcement

Pharma firm $MDCO said that it has completed the patient enrollment in the ORION-1 study of PCSK9si along with its partner $ALNY. 480 patients with high cardiovascular risk and high bad cholesterol were enrolled in this study. Treatment results are anticipated by the end of 2016.

$MDCO {{ '2016-05-27T06:31:03+0000' | timeago}} • Announcement

Pharmaceutical company $MDCO said it has completed patient enrollment in Phase 3 TANGO 1 study of CARBAVANCE, an agent developed for treating complicated urinary tract infections (cUTI). TANGO 1 was initiated in 4Q14 under a cost-share agreement with BARDA to support the development of CARBAVANCE. Topline data are expected in 2H16.

$MDCO {{ '2016-05-16T11:57:29+0000' | timeago}} • Announcement

Medical solutions provider $MDCO said it has appointed Tony Kingsley, previously EVP, Global Commercial Operations at $BIIB, as COO. Kingsley will help oversee the day-to-day operations of the company and will lead the company's commercial activities.

$MDCO {{ '2016-05-09T15:42:28+0000' | timeago}} • Announcement

In addition to generating substantial non-dilutive cash, $MDCO expects the transaction and related restructuring to reduce the company's annual selling, general and administrative and related research and development expenses by between $65MM and $80MM.

$MDCO {{ '2016-05-09T15:40:53+0000' | timeago}} • Announcement

$MDCO said the total consideration of $792MM consists of $260MM in cash payable at closing, up to $480MM in sales-based milestone payments, the assumption by Chiesi of up to $50MM in milestone payment obligations and about $2MM for product inventory.

$MDCO {{ '2016-05-09T15:39:13+0000' | timeago}} • Announcement

$MDCO said it has agreed to divest non-core cardiovascular assets to Chiesi Farmaceutici. $MDCO will sell Cleviprex, Kengreal and the company's rights to Argatroban for Injection to Chiesi USA and its parent company, Chiesi Farmaceutici, for up to $792MM. The transaction is expected to close early in 3Q16.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
OPK (Opko Health, Inc.)
Tuesday, August 8 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
CBM (Cambrex Corporation.)
Friday, August 4 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Thursday, July 27 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
PTX (Pernix Therapeutics Holdings, Inc.)
Monday, May 15 2017 - 8:30pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm

AlphaGraphics you may like